Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

34 results about "Time to peak" patented technology

Active ingredient composition for treating alcoholic liver injury

ActiveCN102028701AClinical dosage is accurate, safe and effectiveEasy to useDigestive systemHeterocyclic compound active ingredientsSide effectHalf-life
The invention discloses an active ingredient composition for treating alcoholic liver injury, and relates to an active ingredient composition for treating liver injury. The invention solves the problems that the conventional traditional Chinese medicines and compound decoction thereof for treating liver injury are inconvenient to use, and the dosage and safety are difficult to control. The active ingredient composition for treating the alcoholic liver injury consists of 6,7-dimethoxybenzopyran-2-one, geniposide and parietic acid. The active ingredient composition for treating the alcoholic liver injury has the advantages that: the clinical medicinal dosage is accurate, safe and effective, the active ingredient composition is convenient to use, the treatment effect is improved, medicinal materials are saved, and toxic and side effects are reduced; and the 6,7-dimethoxybenzopyran-2-one, the geniposide and the parietic acid have liver-protecting and gut-benefiting components having the advantages of quick absorption (short time to peak), slow metabolism (longer half life of medicines), higher peak concentration and larger blood concentration area under a curve, so the 6,7-dimethoxybenzopyran-2-one, the geniposide and the parietic acid can serve as preferred active ingredients. The active ingredient composition provides a basis for subsequently preparing finished pharmaceutical products in various formulations.
Owner:王喜军

Chlorpheniramine maleate compound and pharmaceutical composition thereof

The invention belongs to the technical field of medicine, and particularly relates to a chlorpheniramine maleate compound and a pharmaceutical composition of the chlorpheniramine maleate compound. The chlorpheniramine maleate compound has a chemical structure formula seen in the formula (I) and is measured through an X-ray power diffraction measurement method, and an X-ray power diffraction pattern which is expressed by a diffraction angle of 2 theta+/-0.2 degrees can be seen in the drawing 1. The chlorpheniramine maleate compound is a new crystal form compound different from existing chlorpheniramine maleate in the prior art. The time to peak and the half-life period of chlorpheniramine in pseudoephedrine hydrochloride and chlorphenamine maleate tablets prepared through the new crystal form compound are obviously shortened, the differences between the time to peak and the half-life period of the chlorpheniramine and the time to peak and the half-life period of ibuprofen and the differences between the time to peak and the half-life period of the chlorpheniramine and the time to peak and the half-life period of the pseudoephedrine hydrochloride are reduced, time for allowing concentration of active ingredients of the three types of medicine in blood to reach the effective concentration and time for allowing activity of the active ingredients of the three types of medicine to fade away are kept the same as much as possible, and therefore the pharmacological function of the pseudoephedrine hydrochloride and chlorphenamine maleate tablets is enhanced cooperatively.
Owner:ANHUI YOUCARE KAIYUE PHARMA

A kind of chlorpheniramine maleate compound and its pharmaceutical composition

The invention belongs to the technical field of medicine, and particularly relates to a chlorpheniramine maleate compound and a pharmaceutical composition of the chlorpheniramine maleate compound. The chlorpheniramine maleate compound has a chemical structure formula seen in the formula (I) and is measured through an X-ray power diffraction measurement method, and an X-ray power diffraction pattern which is expressed by a diffraction angle of 2 theta+ / -0.2 degrees can be seen in the drawing 1. The chlorpheniramine maleate compound is a new crystal form compound different from existing chlorpheniramine maleate in the prior art. The time to peak and the half-life period of chlorpheniramine in pseudoephedrine hydrochloride and chlorphenamine maleate tablets prepared through the new crystal form compound are obviously shortened, the differences between the time to peak and the half-life period of the chlorpheniramine and the time to peak and the half-life period of ibuprofen and the differences between the time to peak and the half-life period of the chlorpheniramine and the time to peak and the half-life period of the pseudoephedrine hydrochloride are reduced, time for allowing concentration of active ingredients of the three types of medicine in blood to reach the effective concentration and time for allowing activity of the active ingredients of the three types of medicine to fade away are kept the same as much as possible, and therefore the pharmacological function of the pseudoephedrine hydrochloride and chlorphenamine maleate tablets is enhanced cooperatively.
Owner:ANHUI YOUCARE KAIYUE PHARMA

A kind of immunomodulator sustained-release agent and preparation method thereof

The invention discloses an immunomodulator slow-release preparation and a preparation method thereof. A lenalidomide slow-release tablet is composed of a slow-release layer and an optional quick-release layer, wherein the slow-release layer contains active ingredients of lenalidomide and a slow-release framework material simultaneously; the quick-release layer does not contain the slow-release framework material. The lenalidomide slow-release tablet disclosed by the invention is capable of slowly and uniformly releasing medicines by virtue of the slow-release framework material, so as to reduce the release speed, delay the time to peak, prolong the action time of lenalidomide, and provide a uniform and constant blood concentration. Moreover, The lenalidomide slow-release tablet disclosed by the invention is simple in prescription and excellent in quality stability; the preparation process is simple to operate, free from special treatment and production equipment, low in production cost, and beneficial to batch-enlarged industrial production for the product; the preparation method is high in yield, the granulation and crushing procedures are simple and practicable to operate, the intermediate material is good in stability, flowability, compressibility and content uniformity, and completely meets the requirements of tabletting, and the surface of the prepared tablet is smooth and beautiful.
Owner:AC PHARMA CO LTD

Active ingredient composition for treating alcoholic liver injury

The invention discloses an active ingredient composition for treating alcoholic liver injury, and relates to an active ingredient composition for treating liver injury. The invention solves the problems that the conventional traditional Chinese medicines and compound decoction thereof for treating liver injury are inconvenient to use, and the dosage and safety are difficult to control. The active ingredient composition for treating the alcoholic liver injury consists of 6, 7-dimethoxybenzopyran-2-one, geniposide and parietic acid. The active ingredient composition for treating the alcoholic liver injury has the advantages that: the clinical medicinal dosage is accurate, safe and effective, the active ingredient composition is convenient to use, the treatment effect is improved, medicinal materials are saved, and toxic and side effects are reduced; and the 6,7-dimethoxybenzopyran-2-one, the geniposide and the parietic acid have liver-protecting and gut-benefiting components having the advantages of quick absorption (short time to peak), slow metabolism (longer half life of medicines), higher peak concentration and larger blood concentration area under a curve, so the 6, 7-dimethoxybenzopyran-2-one, the geniposide and the parietic acid can serve as preferred active ingredients. The active ingredient composition provides a basis for subsequently preparing finished pharmaceutical products in various formulations.
Owner:王喜军
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products